Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Cash (2019 - 2025)

Historic Change in Cash for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$106.0 million.

  • BridgeBio Pharma's Change in Cash rose 2515.59% to -$106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.2 million, marking a year-over-year increase of 30403.56%. This contributed to the annual value of $288.5 million for FY2024, which is 140241.96% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Change in Cash of -$106.0 million as of Q3 2025, which was up 2515.59% from $208.4 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Change in Cash peaked at $275.4 million during Q4 2024, and registered a low of -$198.0 million during Q3 2021.
  • Over the past 5 years, BridgeBio Pharma's median Change in Cash value was $13.1 million (recorded in 2022), while the average stood at $15.1 million.
  • In the last 5 years, BridgeBio Pharma's Change in Cash soared by 254818.64% in 2021 and then plummeted by 26976.22% in 2025.
  • BridgeBio Pharma's Change in Cash (Quarter) stood at $213.3 million in 2021, then plummeted by 132.3% to -$68.9 million in 2022, then tumbled by 87.82% to -$129.4 million in 2023, then soared by 312.79% to $275.4 million in 2024, then plummeted by 138.5% to -$106.0 million in 2025.
  • Its last three reported values are -$106.0 million in Q3 2025, $208.4 million for Q2 2025, and -$140.5 million during Q1 2025.